CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Company profile

Ticker

CASI

Exchange

NASDAQ

Website

www.casipharmaceuticals.com

CEO

Wei-Wu He

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...

Former names

ENTREMED INC

SEC CIK

0000895051

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

CASI Pharmaceuticals (China) Co., Ltd, a company of limited • Beijing Zhongbai Biotechnology Co., Ltd. • Miikana Therapeutics, Inc. • CASI Biopharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (Hainan) Co., Ltd., a company of limited ...

IRS number

581959440

CASI stock data

1M 1Y 5Y

News

From Benzinga Pro

41 Stocks Moving In Monday's Mid-Day Session

16 May 22

Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.

30 Stocks Moving in Monday's Pre-Market Session

16 May 22

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $3

16 May 22

HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $4 to $3.

CASI Pharmaceuticals: Q1 Earnings Insights

12 May 22

Recap: CASI Pharmaceuticals Q1 Earnings

12 May 22

Press releases

From Benzinga Pro

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

12 May 22

ROCKVILLE, Md. and BEIJING, May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

2 May 22

ROCKVILLE, Md. and BEIJING, May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT

1 Apr 22

ROCKVILLE, Md. and BEIJING, April 1, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE

28 Mar 22

CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022

23 Mar 22

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 22

17 May 22

31 Dec 22

Financial summary

Financial statements Chart CASI financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	29.26M	29.26M	29.26M	29.26M	29.26M	29.26M
Cash burn (monthly)	3.15M	3.24M	2.8M	2.89M	1.41M	1.92M
Cash used (since last report)	4.89M	5.03M	4.35M	4.49M	2.2M	2.99M
Cash remaining	24.37M	24.23M	24.91M	24.77M	27.06M	26.27M
Runway (months of cash)	7.7	7.5	8.9	8.6	19.2	13.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

CASI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 21	Alexander A Zukiwski	Employee Stock Option Common Stock	Grant	Dispose A	No	No	0.87	500,000	435K	500,000
18 Nov 21	He Wei-Wu	Common Stock	Buy	Acquire P	No	No	0.98	200,000	196K	5,558,472
17 Nov 21	He Wei-Wu	Common Stock	Buy	Acquire P	No	No	0.99	200,000	198K	5,362,569
19 Aug 21	He Wei-Wu	Common Stock	Buy	Acquire P	No	No	1.26	180,000	226.8K	5,163,994
18 Aug 21	He Wei-Wu	Common Stock	Buy	Acquire P	No	No	1.29	300,000	387K	4,983,994
24 Jul 21	Zhang Larry	Employee Stock Option Common Stock	Grant	Dispose A	No	No	1.28	800,000	1.02M	800,000
15 Jun 21	Salisbury Franklin Cary jr	Stock Option Common Stock	Grant	Acquire A	No	No	1.65	110,459	182.26K	110,459

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q4 2021

CASI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cyclacel Pharmaceuticals • Adaptimmune Therapeutics

Management Discussion

Product sales consist of sales of EVOMELA® that launched during August 2019. Revenue was $9.0 million for the three months ended March 31, 2022 compared to $5.7 million for the three months ended March 31, 2021. Revenues increased by 58% in the first quarter of 2022 as compared to same quarter in 2021 due to the continued growth in EVOMELA® sales.
Lease income consists primarily of an equipment lease with Juventas (a related party). Lease income was $37,000 and $36,000, respectively, for the three months ended March 31, 2022 and 2021.
Cost of revenues consists primarily of the cost of inventories of EVOMELA® and sales-based royalties related to the sale of EVOMELA®.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accredited, America, analogy, approximately, Assistance, ASU, attributable, auditor, Barcelona, bid, bill, billion, BioHealth, CDE, Center, certainty, CNCT, consecutive, create, CRPCGIT, CTA, cytotoxic, enhance, esteve, expenditure, FASB, firm, follicular, founder, France, Genetic, Group, guidance, haemopoietic, headquartered, Healthcare, HFCAA, HGRAC, IA, inspect, inspection, issuance, led, mantle, manufactory, marginal, notify, passed, PCAOB, permitted, PK, PRC, prohibit, prohibited, prohibition, prospectively, provision, Recommended, registered, rely, repurchase, repurchased, restriction, retrospectively, revision, run, satisfy, scientific, Senate, shutdown, Spain, stage, submit, submitted, suggested, terminated, threat, Topic, unanticipated, unpaid, withdrawal

Removed: accessible, Accretion, achievement, acquire, activity, addressing, adult, Aid, allocated, Allocation, alternate, annualized, annum, appointed, arise, arrangement, Article, assume, attend, audited, automatically, award, bankruptcy, bear, behalf, BioCheck, book, Branch, build, California, call, candidate, capitalized, carrier, CCA, Chartwell, CITIC, cloud, collected, combined, comparable, compensating, confidence, considerable, consideration, consisting, consolidation, constraint, continuing, controlling, converted, conveyed, Corporation, CRGK, customer, data, decline, deemed, delayed, depend, derecognized, derived, designated, director, disbursed, discontinued, disease, disposal, dissolution, distancing, divided, dividend, dosing, Dr, duty, Electronic, eliminated, embedded, enactment, Engineering, enrollment, Enterprise, entitled, entity, estimable, estimation, evidenced, execution, expired, factor, factory, federal, fixed, Flexibility, forgiven, framework, funded, gain, granted, guarantee, guaranteed, guard, Guokang, HCW, health, hierarchical, highest, holder, Huicun, identification, Incentive, increasing, Industry, infection, influence, initially, initiation, institution, instrument, Jintou, lab, large, lead, lender, life, line, liquidation, loan, lowest, mandated, mandatorily, mandatory, manufacturer, marketed, MaxCyte, maximum, measuring, meet, member, method, microtubule, Miikana, monthly, negatively, newly, observability, observer, occur, occurred, orderly, ordinary, Organization, organized, ownership, parent, participant, partnership, pattern, paused, Paycheck, percent, performance, permanent, Ph, pharmacology, Philadelphia, planned, PPP, PPPFA, predicted, preference, preferred, presentation, prioritization, priority, privately, progressed, prolongation, promissory, protocol, put, quarantine, radiotherapeutic, rational, read, receive, receiving, recognition, recognize, record, recruitment, redeem, Regulation, relapse, relevant, Relief, remain, represented, requisite, resolved, retain, retroactive, reverse, review, round, Rx, SBA, security, segment, SEK, selected, service, settle, settled, shareholder, sheet, shipment, site, social, space, speak, split, state, stated, stipulated, stipulation, stockholder, subscribe, subsequently, subsidiary, substantive, summary, susceptible, systematic, temporary, tranche, transaction, transfer, transferred, travel, treat, type, unadjusted, unfold, unit, unsecured, vendor, vesting, voting, yield

From filing 10-Q 2022 Q1

Financial reports

View all